De-identified Health Data Market Size & Growth Forecast 2027–2036, By Segments (Type of Data, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
De-identified Health Data Market size was assessed at USD 9.6 billion in 2026 and is poised to grow at a 8.93% CAGR between 2027 and 2036, reaching USD 22.58 billion by 2036. The industry revenue for 2027 is calculated at USD 10.32 billion.
Get more details on this report
Request Free Sample ReportDe-identified Health Data Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 37.42% of the market in 2026, driven by advanced healthcare IT infrastructure, widespread electronic health record adoption, and strong demand for compliant secondary data use.
- Asia Pacific is expected to expand at a 10.4% CAGR as healthcare digitization, electronic records adoption, and growing use of analytics generate more de-identified data for research and commercial applications.
Segment Momentum
- Clinical Data accounted for an 18.81% share in 2026 because it is consistently generated, well-structured, and widely used for care delivery, outcomes analysis, population health management, and operational benchmarking.
- Pharmaceutical Companies are the fastest-growing end users as they increasingly rely on de-identified health data to support trial design, patient stratification, safety monitoring, and real-world evidence generation across product development.
Market Expansion Drivers
- Rising adoption of AI-driven healthcare analytics increasing demand for privacy-compliant clinical datasets.
- Expanding electronic health record and wearable device data enabling large-scale secondary healthcare research.
- Growing cross-institutional data collaborations accelerating innovation in personalized medicine and diagnostics.
Leading Market Participants
- Major companies in the de-identified health data market include IQVIA Inc. (United States), Oracle Corporation (United States), UnitedHealth Group (Optum) (United States), ICON plc (Ireland), IBM Corporation (United States), Komodo Health Inc. (United States), Dassault Systèmes (Medidata Solutions) (France), Premier Inc. (United States), Flatiron Health (United States), Veradigm LLC (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 9.6 billion
- 2027 Estimated Market Size: USD 10.32 billion.
- Projected Market Size: USD 22.58 billion by 2036
- Growth Forecast: 8.93% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Clinical Data (Type of Data) | Healthcare Providers (End-use) | Clinical Research and Trials (Application)
- Emerging Opportunity Segment: Genomic Data (Type of Data) | Pharmaceutical Companies (End-use) | Drug Discovery and Development (Application)
Market Growth Drivers and Industry Trends
Rising adoption of AI-driven healthcare analytics increasing demand for privacy-compliant clinical datasets
The de-identified health data market is gaining momentum as healthcare organizations increasingly apply artificial intelligence to clinical analytics, patient stratification, disease prediction, and treatment optimization. AI systems require broad and representative datasets to train and validate models, while privacy requirements limit the use of directly identifiable patient information. De-identified datasets provide a practical means of accessing clinically meaningful information while reducing exposure to sensitive personal data, supporting wider adoption of AI-enabled healthcare applications and analytics workflows.
Expanding electronic health record and wearable device data enabling large-scale secondary healthcare research
The rapid expansion of electronic health records and data generated by wearable devices is creating a deeper pool of longitudinal and real-world health information for secondary research, supporting growth in the de-identified health data market. Digitized clinical records can provide detailed information on diagnoses, treatments, outcomes, and healthcare utilization, while wearable devices contribute continuous data related to activity and physiological parameters. When appropriately de-identified, these diverse datasets can support population studies, outcomes research, clinical development, and healthcare analytics without directly exposing individual identities.
Growing cross-institutional data collaborations accelerating innovation in personalized medicine and diagnostics
Cross-institutional data sharing is strengthening the de-identified health data market by enabling healthcare providers, researchers, and other institutions to combine complementary datasets for broader analysis. Access to information from multiple clinical settings can improve the diversity and representativeness of datasets used to identify disease patterns, evaluate treatment responses, and develop diagnostic approaches. De-identification facilitates these collaborations by helping institutions share useful clinical information while addressing privacy constraints, allowing larger datasets to support research into patient-specific therapies and diagnostic methods.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising adoption of AI-driven healthcare analytics increasing demand for privacy-compliant clinical datasets | 2.00% | High | North America, Europe | High | Near Term |
| Expanding electronic health record and wearable device data enabling large-scale secondary healthcare research | 1.80% | Moderate | North America, Asia Pacific | High | Mid Term |
| Growing cross-institutional data collaborations accelerating innovation in personalized medicine and diagnostics | 1.50% | High | North America, Europe | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share of the de-identified health data market at 37.42% in 2026, supported by advanced healthcare infrastructure, widespread adoption of digital health technologies, and a strong ecosystem for health data analytics. The region's extensive use of electronic health records and other digital systems generates substantial demand for privacy-preserving data that can support clinical research, population health management, healthcare optimization, and artificial intelligence applications. Mature data governance practices and growing emphasis on protecting patient privacy while enabling secondary data use further encourage healthcare organizations and research institutions to adopt de-identification solutions. Continued investment in healthcare digitization and data-driven decision-making reinforces the region's leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing region, driven by rapid digitalization of healthcare systems, expanding adoption of electronic medical records, and increasing interest in using health data to improve clinical and operational outcomes. Growing healthcare expenditure and the modernization of hospitals and diagnostic networks are creating larger volumes of digital health information, increasing the need for secure approaches to data utilization. At the same time, rising awareness of data privacy and the development of regulatory frameworks are encouraging healthcare providers, researchers, and technology organizations to strengthen their data protection capabilities. The combination of expanding digital infrastructure and increasing demand for analytics-based healthcare services is supporting strong regional momentum.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Privacy-Centered Data ExchangeGermany emphasizes de-identified health data solutions that balance research collaboration with rigorous privacy and data protection requirements. Healthcare institutions increasingly invest in standardized anonymization practices to support trusted clinical and scientific data sharing.
France 🇫🇷
Clinical Research CollaborationFrance continues to strengthen the availability of de-identified health data for academic and clinical research initiatives. Healthcare organizations emphasize interoperable data management practices that improve research accessibility while preserving patient privacy and regulatory alignment.
Italy 🇮🇹
Digital Health IntegrationItaly is increasing the use of de-identified health data to support healthcare digitalization and evidence-based decision-making. Institutions focus on improving data standardization and secure information exchange to strengthen collaboration across clinical research and healthcare delivery.
Japan 🇯🇵
Healthcare Analytics EnablementJapan is advancing the use of de-identified health data to strengthen healthcare analytics, medical research, and digital health innovation. Data custodians increasingly focus on high-quality datasets that support evidence generation while protecting patient confidentiality.
South Korea 🇰🇷
AI Data InfrastructureSouth Korea is expanding de-identified health data initiatives to accelerate healthcare artificial intelligence and precision medicine applications. Organizations prioritize secure data integration platforms that facilitate research collaboration while meeting evolving governance expectations.
United States 🇺🇸
Research Data CommercializationThe U.S. continues to expand the use of de-identified health data across clinical research, life sciences, and artificial intelligence development. Organizations prioritize secure data governance frameworks that enable responsible data sharing while maintaining regulatory compliance and research value.
De-identified Health Data Market Share (%), by Type of Data, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType of Data Segment Analysis: Clinical Data (Largest Segment) vs Genomic Data (Fastest-Growing Segment)
Clinical data held the largest share of the de-identified health data market at 18.81% in 2026, reflecting its central role in patient care, healthcare research, population health management, and clinical decision-making. De-identified records containing diagnoses, treatment histories, procedures, and other care-related information provide valuable datasets for analyzing disease patterns and improving healthcare delivery while reducing exposure of personally identifiable information. The increasing digitization of medical records and growing emphasis on data-driven healthcare are reinforcing demand for secure and usable clinical datasets.
Genomic data is emerging as the fastest-growing data category as advances in precision medicine increase the value of genetic information for research and therapeutic development. De-identification enables genomic datasets to be used for population-level analysis while supporting privacy requirements, creating opportunities for research into disease susceptibility, treatment response, and biological mechanisms. Growing interest in personalized medicine, genomic research, and data-intensive drug discovery is therefore strengthening demand for appropriately managed genomic datasets.
End-use Segment Analysis: Healthcare Providers (Largest Segment) vs Pharmaceutical Companies (Fastest-Growing Segment)
In the de-identified health data market, healthcare providers represented the largest end-use segment in 2026, supported by their need to analyze patient information for clinical improvement, care management, operational planning, and population health initiatives. De-identified data allows providers to extract insights from large patient populations while reducing privacy risks associated with direct patient identification. The expanding use of digital health records and analytics-based care models is further increasing the importance of accessible, privacy-conscious health data.
Pharmaceutical companies are experiencing faster growth in the use of de-identified health data as drug development increasingly depends on real-world evidence and more detailed understanding of patient populations. Such datasets can support clinical research, patient stratification, treatment outcome analysis, and post-market evaluation while helping organizations work with sensitive information under privacy constraints. The growing emphasis on evidence-based development and personalized therapies is consequently expanding pharmaceutical demand for high-quality de-identified datasets.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type of Data | Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Claims Data, Behavioral Data, Wearable and Sensor Data, Survey and Patient-Reported Data, Imaging Data, Laboratory Data, Social Determinants of Health (SDoH) Data, Pharmacogenomic Data, Biometric Data, Operational and Financial Data, Epidemiological Data, Healthcare Utilization Data, Others | Clinical Data | Genomic Data |
| End-use | Pharmaceutical Companies, Biotechnology Firms, Medical Device Manufacturers, Healthcare Providers, Research Institutions, Others | Healthcare Providers | Pharmaceutical Companies |
| Application | Clinical Research and Trials, Public Health, Precision Medicine, Health Economics and Outcomes Research (HEOR), Population Health Management, Drug Discovery and Development, Healthcare Quality Improvement, Insurance Underwriting and Risk Assessment, Market Access and Commercial Strategy, Business Intelligence and Operational Efficiency, Telemedicine and Remote Monitoring, Patient Engagement and Support Programs, Others | Clinical Research and Trials | Drug Discovery and Development |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the de-identified health data market:
1. IQVIA Inc. (United States)
2. Oracle Corporation (United States)
3. UnitedHealth Group (Optum) (United States)
4. ICON plc (Ireland)
5. IBM Corporation (United States)
6. Komodo Health Inc. (United States)
7. Dassault Systèmes (Medidata Solutions) (France)
8. Premier Inc. (United States)
9. Flatiron Health (United States)
10. Veradigm LLC (United States)
Increasing reliance on data-driven healthcare insights is accelerating growth in the de-identified health data market. Organizations are implementing advanced anonymization technologies, AI-powered analytics, and interoperable data platforms to support research, population health management, and clinical innovation. Strategic collaborations focused on secure data sharing and compliance optimization are also strengthening the value of de-identified healthcare datasets.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| IQVIA Inc. (United States) | |||||||
| Oracle Corporation (United States) | |||||||
| UnitedHealth Group (Optum) (United States) | |||||||
| ICON plc (Ireland) | |||||||
| IBM Corporation (United States) | |||||||
| Komodo Health Inc. (United States) | |||||||
| Dassault Systèmes (Medidata Solutions) (France) | |||||||
| Premier Inc. (United States) | |||||||
| Flatiron Health (United States) | |||||||
| Veradigm LLC (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| UK Biobank | Mar-26 | The accidental disclosure of volunteers’ de-identified health data by researchers has highlighted critical governance challenges in the management of large-scale biomedical repositories. This incident underscores ongoing operational risks and the necessity for enhanced privacy safeguards and stricter access control frameworks for researchers utilizing distributed secondary health datasets. |
| NHS | Feb-26 | The UK government has mandated the development of technical infrastructure for the NHS to facilitate the use of anonymized primary care patient data for research. This initiative aims to establish a secure, large-scale framework for data sharing, enabling expanded access to national health datasets for medical and public health research while enforcing rigorous de-identification standards. |
| Great Ormond Street Hospital | Feb-26 | The Great Ormond Street Hospital for Children NHS Foundation Trust partnered with a charitable entity to integrate pediatric health data for rare disease research. This initiative focuses on improving data linkage and accessibility across clinical and research systems, enhancing collaborative capabilities to support the analysis of rare conditions and advance pediatric healthcare outcomes. |
| Amazon Web Services | Nov-25 | The government of La Rioja, through Fundación Rioja Salud, launched the PASCAL health data lake on Amazon Web Services infrastructure. This cloud-based platform consolidates health data into a unified environment to support predictive, preventive, and precision medicine, providing the analytical capacity required for data-driven healthcare innovation and large-scale clinical research applications. |
| ICON | Sep-24 | ICON entered a strategic collaboration with Intel to leverage de-identified data from its clinical research platform alongside Intel's AI technology. The partnership focuses on optimizing patient recruitment and streamlining clinical trial workflows, utilizing large-scale data insights to improve precision medicine and increase overall efficiency in the drug development pipeline. |
| Seqster | Mar-24 | The Multiple Sclerosis Implementation Network adopted the Seqster operating system to standardize health data sharing and management for neurological research. The platform facilitates the integration and coordination of patient data across diverse stakeholders, improving research workflow efficiency and enabling evidence-based clinical decision-making within the treatment of multiple sclerosis. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
De-identified Health Data Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Data Source | Electronic Health Records, Claims and Administrative Data, Clinical Research Data, Patient-Generated Data, Genomic and Molecular Data |
| Data Access Model | Subscription-Based Access, Pay-Per-Use Access, Enterprise Licensing, Data-as-a-Service |
| Geographic Coverage | Local and Regional Data, National Data, Multi-Country Data, Global Data |
De-identified Health Data Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Data Monetization Opportunity Assessment |
|
| Privacy-Preserving Innovation Landscape |
|
| AI-Driven Data Utilization Outlook |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market valuation of de-identified health data?
What are the growth projections for the de-identified health data industry?
How is AI-driven healthcare analytics shaping demand for de-identified clinical datasets?
How are EHR systems and wearable devices expanding secondary healthcare research use cases?
Why is Clinical Data the leading data type in the de-identified health data market?
Why are Pharmaceutical Companies the fastest-growing end users in the de-identified health data market?
Why is North America the largest de-identified health data market?
What factors are accelerating de-identified health data market growth in Asia Pacific?
Which companies dominate the de-identified health data landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook